Ciprofloxacin Pharmacokinetics in Critically Ill Patients on Haemodiafiltration
Author Information
Author(s): Spooner Almath M, Deegan Catherine, D'Arcy Deirdre M, Gowing Caitriona M, Donnelly Maria B, Corrigan Owen I
Primary Institution: School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin
Hypothesis
The study aimed to investigate the pharmacokinetics of intravenous ciprofloxacin in critically ill ICU patients undergoing continuous veno-venous haemodiafiltration.
Conclusion
A dose rate of 400 mg every 12 hours may be necessary to achieve the desired pharmacokinetic goals in patients on CVVHDF.
Supporting Evidence
- The median half-life of ciprofloxacin was found to be 13.8 hours.
- Ciprofloxacin clearance by CVVHDF was on average 26% of the total body clearance.
- The study suggests that creatinine clearance can be used as a surrogate for ciprofloxacin clearance.
Takeaway
This study looked at how well a medicine called ciprofloxacin works in very sick patients who are getting special kidney treatment. It found that they might need a higher dose to help fight infections.
Methodology
An open prospective study with blood and ultrafiltrate samples collected from seven critically ill patients on CVVHDF.
Limitations
The small number of patients limits the generalizability of the findings.
Participant Demographics
Seven critically ill patients with sepsis requiring CVVHDF, including a mix of genders and ages ranging from 28 to 77 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website